SII, DNDi partner for expanding human trials for dengue treatment
The Pune-based Serum Institute of India (SII) has partnered with Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organisation, to accelerate the clinical development of a monoclonal antibody (mab) treatment for dengue that will be affordable and accessible in low- and middle-income countries (LMICs). Mab are lab-produced antibodies, meant to mimic the…